SCHEMBL825790

SCHEMBL825790

N#Cc1cccc2sc(C(=O)N=C(N)N)cc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
SLC9A1 P19634 20/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31117978 0.84 SLC9A1 (0.72) SLC9A1
SCHEMBL826149 0.81 SLC9A1 (0.68) SLC9A1
SCHEMBL828833 0.81 SLC9A1 (0.75) SLC9A1
SCHEMBL826041 0.80 SLC9A1 (0.74) SLC9A1
SCHEMBL825789 0.80 SLC9A1 (1.00) SLC9A1
SCHEMBL826075 0.79 SLC9A1 (1.00) SLC9A1
SCHEMBL825759 0.79 SLC9A1 (1.00) SLC9A1
SCHEMBL825953 0.79 SLC9A1 (1.00) SLC9A1
SCHEMBL825760 0.78 SLC9A1 (1.00) SLC9A1
SCHEMBL826052 0.77 SLC9A1 (1.00) SLC9A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12533309-B2 Minoxidil adjuvant therapies CARING BRANDS, INC. (US) 2026-01-27 US disclosed
US-12527729-B2 Minoxidil adjuvant therapies CARING BRANDS, INC. (US) 2026-01-20 US disclosed
US-20250360128-A1 MINOXIDIL ADJUVANT THERAPIES JUPITER WELLNESS INC (US) 2025-11-27 US disclosed
EP-4536354-A1 MINOXIDIL ADJUVANT THERAPIES Jupiter Wellness, Inc. (US) 2025-04-16 EP disclosed
US-20240009101-A1 MINOXIDIL ADJUVANT THERAPIES Jupiter Wellness, Inc. (US) 2024-01-11 US disclosed
US-20230404886-A1 MINOXIDIL ADJUVANT THERAPIES Jupiter Wellness, Inc. (US) 2023-12-21 US disclosed
CN-117243839-A Minoxidil adjuvant therapy 应用生物学股份有限公司 2023-12-19 CN disclosed
US-11766392-B2 Minoxidil adjuvant therapies Jupiter Wellness, Inc. (US) 2023-09-26 US disclosed
US-11628132-B2 Minoxidil adjuvant therapies Jupiter Wellness, Inc. (US) 2023-04-18 US disclosed
US-20220296486-A1 Minoxidil Adjuvant Therapies Jupiter Wellness, Inc. 2022-09-22 US disclosed
US-8143307-B2 Benzothiophen-2-carbonylguanidine derivatives, preparation thereof, and pharmaceutical composition containing the same KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2012-03-27 US disclosed
US-8143307-B2 Benzothiophen-2-carbonylguanidine derivatives, preparation thereof, and pharmaceutical composition containing the same KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2012-03-27 US disclosed
US-20100004466-A1 Benzothiophen-2-carbonylguanidine derivatives, preparation thereof, and pharmaceutical composition containing the same KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-01-07 US disclosed
US-20100004466-A1 Benzothiophen-2-carbonylguanidine derivatives, preparation thereof, and pharmaceutical composition containing the same KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-01-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12527729-B2 Minoxidil adjuvant therapies RXRA, RXRB, RXRG SLC9A1 236/4885
US-20100004466-A1 Benzothiophen-2-carbonylguanidine derivatives, preparation thereof, and pharmaceutical composition containing the same TNNI3, TNNT2, SLC9A2 SLC9A1 5/4885
US-12533309-B2 Minoxidil adjuvant therapies RXRG, RXRA, RXRB SLC9A1 357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.